MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies. Licensed Investment Advisor.
Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Vahan Janjigian is Chief Investment Officer at Greenwich Wealth Management, LLC, an SEC registered investment advisor. He previously served as Chief Investment Strategist at Forbes Media, LLC. He has served on the finance faculties of several universities. Vahan is the author of several books and numerous research papers published in academic journals.
Please note that the article that you are reading here was originally written on my blog and is republished in Seeking Alpha and other forums. Consequently, I neither track nor respond to comments here. I am sorry! ================ Editors' Note: Seeking Alpha monitors Dr. Damodaran blog and posts relevant articles on his behalf.
Mariusz Skonieczny is the founder and president of Classic Value Investors, He is also the author of several books on investing including Why Are We So Clueless about the Stock Market, The Basics of Understanding Financial Statements, Due Diligence: How to Research a Stock, 100 Ways to Find Investment Ideas, Investment Wisdom and Gold Production from Beginning to End.
Our small-cap hedge fund strategy beat the market by 44 percentage points since its inception 18 months ago. Visit our website to learn how you can do the same. Insider Monkey is a finance website that provides free hedge fund and insider trading data. We believe ordinary investors can beat the market by imitating insiders and best hedge fund managers. They have access to better information and experts than ordinary investors do. Take advantage of the SEC filings where hedge funds and insiders disclose their stock transactions.
Here is our team:
Ms. Krishnamsetty is the Editor of Insider Monkey. Prior to creating Insider Monkey with Dr. Dogan, Ms. Krishnamsetty was Associate Producer at Bloomberg Television. Prior to that, Ms. Krishnamsetty was on the afternoon news team at CNBC. Additionally, Ms. Krishnamsetty reported for NPR and worked as a risk management consultant at Marsh & McLennan. Ms. Krishnamsetty has a M.S. in Journalism from Columbia University’s Graduate School of Journalism.
Insider Monkey’s hybrid evaluation system ...More was created in 2003 by Dr. Ian Dogan. Dr. Dogan has a Ph.D. in financial economics with a specialization in insider trading. Dr. Dogan has provided consulting services to institutional investors and hedge funds, and managed a $200+ million fund using a strategy he developed utilizing insider transactions. Dr. Dogan recently authored the insider trading chapter of soon to be published “The Handbook of Investment Anomalies” by Zacks Investment Research. Insider Monkey will serve the outcome of the methodologies developed by Dr. Dogan to ordinary investors who don’t have access to academic quality research and tools to shape their investments.
For your inquiries please contact us at email@example.com
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
Who am I?
My name is Dah Hui Lau, everyone calls me David. I'm 29 years old.
What is my passion?
My passion is in value investing. My dream is to be a great investment manager.
Jack Canfield said:-
"You were born with an inner guidance system that tells you when you are on or off purpose by the amount of joy you are experiencing. The things that bring you the greatest joy are in alignment with our purpose."
Everyone is put on this earth with a life purpose. Only by living and fulfilling one's life purpose does one lives the most meaningful and exciting life. As for me, I experience highest satisfaction when I am indulging in investing activity. I love poring over annual reports of various companies, following ground-breaking news of the companies, anticipating the companies' results and beating the S&P500 and FTSE100 benchmarks.
What is my long-term goal?
1. To be a great investment manager.
2. To give back to the community by sharing of investing knowledge and wisdom.
Visit my sites:
Dah Hui Lau (David) (http://dahhuilaudavid.blogspot.com/)
Lollapalooza Investing (http://lollapaloozainvesting.blogspot.com/)
Sean Daly is Associate Director of Global Strategy at Alpha Creative Capital, a New York-based investment advisory group. He has written extensively on Asian economic development, exploring issues as diverse as Chinese urbanization, CMI multilateral currency swap arrangements, energy geopolitics in Kazakhstan, and Singapore’s high-tech water industry. He was educated at Columbia University and NYU and was a visiting lecturer at Princeton University from 2005 to 2009.
His equity approach is to chart the broader demographic issues of globalization and find sectors, companies, or resources that are likely to benefit from emerging macro-trends.
Opportunities are further refined through fundamental analysis and some basic quantitative techniques. Technical indicators are used exhaustively to determine tactical entry or exit points.
Sean Daly has written on sovereign wealth management for The Deal, a private equity periodical. His most recent analysis of US - ASEAN trade policy was published in the Carnegie Council's magazine, Policy Innovations:
His discussion of China's rare earths diplomacy can also be found there:
Cara Goldenberg is Founding Partner at Permian Investment Partners. Goldenberg got her undergraduate degree in chemistry in 2002 from Yale University in New Haven, Connecticut. Her first job out of college was working as a private-equity analyst at New York-based investment bank Morgan Stanley.
She then moved to Highbridge Capital Management LLC, the hedge- fund firm owned by JPMorgan Chase & Co., in 2003, and to Brahman Capital Corp., also in New York, a year later. She became that firm’s youngest partner, and oversaw a $2 billion European equity portfolio. She and two former Brahman colleagues started Permian with about $65 million in assets in August 2008 and it now manages about $100 million. Permian, which is named for the geologic period that ran from about 290 million to 250 million years ago, focuses on what it deems undervalued companies, mostly in Western Europe.